Copy to clipboard 
Secada Medical (dba Ventris Medical) was granted a patent by the United States Patent and Trademark Office for Producing an Osteoinductive Calcium Phosphate for Bone Grafting. The invention relates to the treatment of biphasic calcium phosphate granules to transform the standard post sintering grain-like surface morphology into a needle-like surface morphology shown to exhibit superior osteoinductivity.
The invention’s biphasic material’s post-processing surface morphology provides increased osteoinductivity and, therefore, a superior artificial bone material suitable for a variety of orthopedic treatments. The invention improves osteoinductivity compared to pre-treated granules and may be used to induce the formation of bone tissue in a patient alone or in combination with growth factors, cells, or other components.
The chemical processing methods of the invention can generate the desired needle-like or nanorod-like surface morphology on any ratio of calcium phosphate to apatite including β-tricalcium phosphate to apatite including β-tricalcium phosphate/hydroxyapatite (βTCP/HA) granules with less than 80% or even 40% βTCP content.
Russell Cook, CEO of Ventris Medical commented, “We continue to develop a robust library of intellectual property that adds to our overall value proposition. This technology, which we will commercialize as Amplify® granules, will become a major component of our synthetic bone graft offerings. It is our company mission to develop next generational devices that bring excitement to our surgeon community as well as our distribution partners.”
John Brunelle, PhD, COO of Ventris Medical added, “The Amplify technology platform is intended to address critical gaps in current treatment algorithms while bringing greater efficiency to the surgeon experience. Our surface-activated granules combine the established clinical efficacy of traditional biphasic materials with state-of-the-art processing techniques, providing a bone graft that is more synchronized with the natural healing process. This milestone sets the stage for future product developments and establishes Ventris as a key innovator in the ortho-biologics space.”
Source: Ventris Medical
Secada Medical (dba Ventris Medical) was granted a patent by the United States Patent and Trademark Office for Producing an Osteoinductive Calcium Phosphate for Bone Grafting. The invention relates to the treatment of biphasic calcium phosphate granules to transform the standard post sintering grain-like surface morphology into a needle-like...
Secada Medical (dba Ventris Medical) was granted a patent by the United States Patent and Trademark Office for Producing an Osteoinductive Calcium Phosphate for Bone Grafting. The invention relates to the treatment of biphasic calcium phosphate granules to transform the standard post sintering grain-like surface morphology into a needle-like surface morphology shown to exhibit superior osteoinductivity.
The invention’s biphasic material’s post-processing surface morphology provides increased osteoinductivity and, therefore, a superior artificial bone material suitable for a variety of orthopedic treatments. The invention improves osteoinductivity compared to pre-treated granules and may be used to induce the formation of bone tissue in a patient alone or in combination with growth factors, cells, or other components.
The chemical processing methods of the invention can generate the desired needle-like or nanorod-like surface morphology on any ratio of calcium phosphate to apatite including β-tricalcium phosphate to apatite including β-tricalcium phosphate/hydroxyapatite (βTCP/HA) granules with less than 80% or even 40% βTCP content.
Russell Cook, CEO of Ventris Medical commented, “We continue to develop a robust library of intellectual property that adds to our overall value proposition. This technology, which we will commercialize as Amplify® granules, will become a major component of our synthetic bone graft offerings. It is our company mission to develop next generational devices that bring excitement to our surgeon community as well as our distribution partners.”
John Brunelle, PhD, COO of Ventris Medical added, “The Amplify technology platform is intended to address critical gaps in current treatment algorithms while bringing greater efficiency to the surgeon experience. Our surface-activated granules combine the established clinical efficacy of traditional biphasic materials with state-of-the-art processing techniques, providing a bone graft that is more synchronized with the natural healing process. This milestone sets the stage for future product developments and establishes Ventris as a key innovator in the ortho-biologics space.”
Source: Ventris Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
